TVARDI THERAPEUTICS, INC.
NASDAQ: TVRD (Tvardi Therapeutics, Inc.)
Last update: 3 hours ago1.24
-0.01 (-0.80%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Tvardi Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.67 |
|
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 27.53% |
| % Held by Institutions | 2.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Slate Path Capital Lp | 30 Jun 2026 | 704,118 |
| American Financial Group Inc | 30 Jun 2026 | 223,659 |
| Silvercrest Asset Management Group Llc | 30 Jun 2026 | 101,034 |
| Duncan Williams Asset Management, Llc | 30 Jun 2026 | 63,241 |
| Russell Investments Group, Ltd. | 30 Jun 2026 | 43,228 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |